Effects of acarbose in β-thalassaemia major patients with normal glucose tolerance and hyperinsulinism

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 2, 2004, Pages 272-275

  Mangiagli, Antonino ^a   Campisi, Saveria ^a   De Sanctis, Vincenzo ^b   Nicoletti, Manuela Caruso ^c   Cardinale, Giuliana ^d   Galati, Maria Concetta ^e   Raiola, Giuseppe ^e   Rigano, Paolo ^f   Saviano, Anna ^g  

^a Umberto I Hospital   (Italy)

^b S ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d F Ferrari Hospital   (Italy)

^e PUGLIESE CIACCIO HOSPITAL   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

Author keywords

Acarbose; Hyperinsulinism; Thalassaemia

Indexed keywords

ACARBOSE; DEFEROXAMINE MESYLATE; GLUCOSE; INSULIN; LIVER ENZYME;

ABDOMINAL CRAMP; AREA UNDER THE CURVE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HYPERINSULINISM; INSULIN BLOOD LEVEL; INSULIN RELEASE; IRON OVERLOAD; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ACARBOSE; ADULT; AREA UNDER CURVE; BETA-THALASSEMIA; BLOOD GLUCOSE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 12544257980     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Wonke B, Hanslip JP. Glucose intolerance and diabetes in thalassaemia major. In: Andò S, Brancati C, Eds. Endocrine Disorders in Thalassaemia. Berlin: Springer-Verlag 1995;65-67
2. Dandona PM, Hussein NAM, Varghese Z. Insulin resistance and iron overload. Ann Clin Biochem 1983;20:77-81
3. De Sanctis V, D'Ascola DG, Wonke B. The development of diabetes mellitus and chronic liver disease in long-term chelated β-thalassaemic patients. Postgrad Med J 1980;62:831-836
4. Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin dependent diabetes mellitus. Drug Safety 1994;11:432-444
5. Inoue J, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. Diab Res Clin Pract 1997;36:143-151
6. Chiasson JL, Josse RE, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-2077
7. Scheen AJ. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63:933-951
8. Mangiagli A, Italia S, De Sanctis V, Campisi S. Impaired glucose homeostasis in young adult thalassaemic patients: a pilot study with acarbose. J Ped Endocrinol Metab 2002;15:205-210
9. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide 1. Diab Metab Res Rev 2002;78:430-441
10. Cario H, Holl RW, Debatin KM, Kohne E. Disproportionately elevated fasting proinsulin levels in normoglycemic patients with thalassaemia major are correlated to the degree of iron overload. Horm Res 2003;59:73-78